Polycystic ovary syndrome is tangled up with insulin resistance, and that is the usual explanation for why a drug like this should help — the same kind of mechanism story that gets told about other hormonal conditions. The pooled trial evidence supports part of it and not the part everyone names.
What exists
A meta-analysis searched four databases for randomized trials of a GLP-1 against placebo in women diagnosed with PCOS by the Rotterdam criteria, and found four. [1] Together they contributed 176 participants — not per arm, in total. Liraglutide accounted for 103 of them, 58 per cent, and semaglutide for 23, or 13 per cent.
That composition matters before any result. Most of what is known here comes from a drug that is not what most people are prescribed now, in a pooled sample smaller than a single modest trial.
What moved
Waist circumference fell by 5.16 cm, 95% CI −6.11 to −4.21, p<0.00001. BMI fell 2.42 points, 95% CI −3.10 to −1.74. Serum triglycerides fell 0.20, 95% CI −0.30 to −0.11. Total testosterone fell by 1.33, 95% CI −2.55 to −0.12, p=0.03 — a real result whose interval comes close to zero.
Adverse event information was available for 112 patients, of whom 49 reported light side effects such as nausea and abdominal pain.
What did not
Total cholesterol showed no significant difference, at −0.04, 95% CI −0.10 to 0.01, p=0.15. Neither did HOMA-IR, at −0.30, 95% CI −0.92 to 0.32, p=0.35.
How much weight to give a null this small
Not much, in either direction. With 176 people across four trials, a real moderate effect on HOMA-IR could easily go undetected. The interval runs from −0.92 to 0.32, which is wide enough to contain a meaningful improvement and a slight worsening at once.
So the correct reading is not that these drugs fail to address insulin resistance in PCOS. It is that nobody has shown they do, on a sample this size, and that the results being quoted as evidence for PCOS treatment are mostly results about weight. That distinction is the same one that separates a famous trial from a thin literature in other corners of this field.
The testosterone question
Hyperandrogenism is what many women with PCOS most want treated — the hair, the skin, the cycles. Total testosterone did fall, significantly. But the pooled estimate is a single laboratory number whose interval nearly reaches zero, drawn from four small trials, and no clinical outcome was pooled alongside it. Whether that translates into anything a person would notice is a different endpoint, and which endpoint a study chose decides what it can tell you.
What this means before ordering
No seller on this roster offers a PCOS service or claims the indication. What is being sold is weight loss, and weight loss genuinely helps many PCOS symptoms — that is not in dispute and does not require this literature.
What would be misleading is a purchase made on the belief that the drug is treating the underlying endocrinology. Four trials and 176 women do not establish that, and the marker closest to the claim is the one that did not move. PCOS care is a gynecologist or endocrinologist’s territory, and the questions a seller leaves unanswered include every one that matters here.